In our study, subgroup analysis showed that short-term (1–4 weeks) to long-term (52 weeks) SGLT2is plus insulin resulted in a larger reduction in HbA1c and FPG levels compared with placebo in T1DM patients. The gene discussed is INS; the disease is type 1 diabetes mellitus.